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Introduction 
Metabolic syndrome has been associated 
with schizophrenia since long before the era 
of antipsychotic medications.1 The 
introduction of atypical antipsychotics has 
been associated with worsened weight gain, 
hyperglycemia, and hypertriglyceridemia.2 
An American Diabetes Association/ 
American Psychiatric Association (ADA/ 
APA) consensus paper recognized that 
certain atypical antipsychotic medications 
are associated with greater metabolic 
dysfunction than others.3  
A case of a young female patient with 
uncontrolled type 2 diabetes mellitus on 
atypical antipsychotics is presented. Her 
antipsychotic medications were discontinued 
due to pregnancy.  The patient subsequently 
had significant weight loss and improvement 
in her glycemic control.   
 
Case Report 
A 35-year-old female was seen in the 
endocrinology clinic for type 2 diabetes 
mellitus complicated by gastroparesis, 
peripheral neuropathy, and nephropathy. 
Glycemic control had not been achieved on 
insulin glargine 40 units twice daily, insulin 
lispro 10 units before meals, pioglitazone 30 
mg daily, and metformin 850 mg twice 
daily.  Hemoglobin A1c was thirteen percent. 
Her past medical history was significant 
for resolved renal failure secondary to 
lithium toxicity, asthma, primary hypo-
thyroidism, bipolar disorder, hyperlipidemia, 
hypertension, and schizophrenia. Other 
medications   included   quetiapine   500  mg  
 
daily in a divided dose, citalopram 40 mg 
daily, divalproex 2500 mg daily, 
aripiprazole 20 mg daily, levothyroxine 100 
mcg daily, lisinopril, pravastatin, 
pantoprazole, docusate, aspirin, propranolol, 
odansetron, promethazine, metoclopramide, 
and trazodone. 
Physical exam revealed a blood pressure 
of 113/69 mmHg, weight 99.5 kg, a body 
mass index (BMI) of 35 kg/m2, mild 
acanthosis nigricans, and decreased 
sensation in both feet.  Cushingoid features 
were not present.  Urine free cortisol in a 24- 
hour collection was not elevated. 
Metformin was discontinued because of 
diarrhea.  The patient attended diabetic 
education sessions and attempted dosing 
insulin by carbohydrate counting without 
success.  The pharmacy confirmed that her 
prescriptions were being filled and she was 
observed taking insulin in clinic with little 
demonstrable effect on her blood glucose. 
She became pregnant and all 
medications were discontinued with the 
exception of insulin, levothyroxine, and 
citalopram.  Acceptable glycemic control 
was achieved on insulin glargine 50 units 
once daily and insulin aspart 27 units three 
times daily. 
Term delivery was complicated by 
failure to progress, resulting in a Cesarean 
section.   The  infant  was  not   macrosomic.   
The patient experienced postpartum 
respiratory failure of uncertain etiology 
requiring brief mechanical ventilation.  
Marked hypoglycemia occurred post-partum  
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and insulin was discontinued.  
She was seen in the endocrinology clinic 
seven weeks post-partum without diabetic or 
antipsychotic medications. Her hemoglobin 
A1c was 6.5 percent and her weight had 
decreased to 81.87 kilograms.  She was not 
breastfeeding. She was restarted on 
metformin 1 gram twice daily and later 
extended release glipizide 5 mg daily. 
Subsequent follow-up showed well 
controlled blood glucose and stable weight. 
 
Discussion 
Schizophrenia has a prevalence of 1%.4 
It is associated with a significant increase in 
mortality. A correlation between diabetes 
mellitus and schizophrenia has been 
observed for many years.  In 1879, Sir 
Henry Maudsley wrote, "Diabetes is a 
disease which often shows in families in 
which insanity prevails.”5 The prevalence of 
type 2 diabetes mellitus in patients with 
schizophrenia is 9% versus 4.6% in the 
general population.6 
The reasons that underlie the high 
prevalence abnormalities are much debated.7 
In spite of the increased risk of metabolic 
disturbances, patients with severe mental 
illness are less likely to receive treatment for 
hyperlipidemia, hypertension, or diabetes 
mellitus than patients without psychosis.8 
Pharmacologic agents used in the 
treatment of schizophrenia, particularly 
second generation antipsychotics, have been 
linked to the metabolic syndrome.  The US 
Food and Drug Administration has labeled 
this as a class effect, although there are 
major differences in risk associated with the 
various medications.9 
Clozapine causes metabolic syndrome in 
more than 50% of long time users.10  The 
risk of new-onset diabetes was equivalent 
for patients treated for one year with 
olanzapine, risperidone, or quetiapine, and 
significantly greater than in patients treated 
with haloperidol.11 Atypical antipsychotics 
also have been associated with a small 
increase in risk of diabetic ketoacidosis.12  In 
a case control study comparing patients 
treated with antipsychotic drugs to control 
patients without antipsychotic medication, 
the odds ratio for hyperlipidemia ranged 
from 1.82 for clozapine to 1.26 for first 
generation antipsychotics; aripiprazole was 
the only antipsychotic that did not increase 
the risk for hyperlipidemia significantly.13 
Several mechanisms have been proposed 
to explain the effect of antipsychotic 
medications on the metabolic syndrome.  
Antipsychotics can disrupt energy balance, 
creating an imbalance between energy 
intake and expenditure, thus resulting in 
weight gain and obesity.14  This can be 
explained partially by antagonism of 
histamine and possibly by serotonin 
inducing weight gain, which in turn leads to 
changes in glucose homeostasis.15  Some 
antipsychotic drugs may have direct 
inhibitory effects on insulin release from 
pancreatic beta cells.16  Other  theories 
include a potential direct blockade of 
glucose accumulation at the level of the 
glucose transporter in cells derived from 
both peripheral and brain tissue,17 
perturbation in appetite regulation, and the 
release of counter regulatory hormones.18 
Treatment.  No adjunctive medication 
has been conclusively shown to reduce these 
metabolic effects.19 Even among drugs 
showing positive effects for preventing 
weight gain, such as metformin, the 
metabolic effects have been modest.  
Patients who develop antipsychotic-induced 
metabolic disturbance should be switched, if 
clinically practical, to an agent with fewer 
propensities for this side effect, such as 
aripiprazole or ziprasidone.  A consensus 
statement prepared by the American 
Psychiatric Association, the American 
Diabetes Association, and others 
recommended baseline assessment of 
weight, blood pressure, fasting plasma 
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glucose, and fasting lipid profile, and 
reassessment 12 weeks after initiation of the 
antipsychotic medication.3  Patients with 
impaired fasting glucose should be tested for 
diabetes with a two-hour oral glucose 
tolerance test. Weight should be followed 
monthly for the first three months and 
quarterly thereafter. 
 
Conclusion 
The association between schizophrenia 
and the metabolic syndrome has long been 
recognized. Unfortunately, metabolic dis-
turbances, including diabetes mellitus, 
hypertension, hyperlipidemia, and weight 
gain, appear to be caused or exacerbated by 
atypical antipsychotics. Several mechanisms 
have been proposed, mainly a perturbation 
of the body’s ability to react, metabolize, 
and transport glucose causing weight gain 
and exacerbating insulin resistance.  Patients 
requiring antipsychotic medications should 
be assessed for aspects of the metabolic 
syndrome before and during treatment.  
Switching to antipsychotic medications not 
related to metabolic disturbances or even 
discontinuing antipsychotic medications 
should be evaluated on an individual patient 
basis. 
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